

**Key highlights of data accepted by ASH include:**

<b>Abstract Title</b>	<b>Abstract Number/ Presentation Details</b>
<b>Ianalumab (VAY736)</b>	
Primary results from VAYHIT2, a randomized, double-blind, Phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment	Abstract #LBA-2 Oral Presentation December 9, 7:45 – 8:00 am ET
Secondary analysis results from VAYHIT3, a Phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy	Abstract #844 Oral Presentation December 8, 3:30 – 3:45 pm ET
<b>Scemblix® (asciminib)</b>	
Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis	Abstract #1997 Poster Presentation December 6, 5:30 – 7:30 pm ET
Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial	Abstract #5549 Poster Presentation December 8, 6:00 – 8:00 pm ET
Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)	Abstract #906 Oral Presentation December 8, 4:00 – 4:15 pm ET
A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase	Abstract #724 Oral Presentation December 7, 5:15 – 5:30 pm ET
<b>Pelabresib (DAK539)</b>	
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naïve myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study	Abstract #910 Oral Presentation December 8, 3:30 – 3:45pm ET
<b>Rapcabtagene autoleucel (YTB323)</b>	
Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: phase II interim results	Abstract #670 Oral Presentation December 7, 5:15 – 5:30 pm ET
<b>Fabhalta® (iptacopan)</b>	
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dL on anti-C5 therapy: Subgroup analysis of the APPULSE-PNH Phase 3b trial	Abstract #4981 Poster Presentation December 8, 6:00 – 8:00 pm ET
Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from phase 2 studies who entered the roll-over extension program	Abstract #3198 Poster Presentation December 7, 6:00 – 8:00 pm ET
The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program	Abstract #4978 Poster Presentation December 8, 6:00 – 8:00 pm ET

**Key highlights of data accepted by SABCS include:**

<b>Kisqali® (ribociclib)</b>	
Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS)	Abstract # PD5-10 Poster Spotlight Presentation December 11, 8:09 – 8:12 am CST

Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC)	Abstract # PS3-09-08 Poster Presentation December 11, 12:30 – 2:00 pm CST
Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC)	Abstract # PS1-10-27 Poster Presentation December 10, 12:30 – 2:00 pm CST
Ribociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patients	Abstract # PS3-09-15 Poster Presentation December 11, 12:30 – 2:00 pm CST
Real-world patient (pt) and caregiver experiences with breast cancer (BC) risk of recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis	Abstract # PS1-04-17 Poster Presentation December 10, 12:30 – 2:00 pm CST
Repower: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET)	Abstract # PS3-08-27 Poster Presentation December 11, 12:30 – 2:00 pm CST